Finerenone
Triple combination therapy using SGLT2i, GLP-1 RA, and finerenone has been modelled to produce substantial gains in cardiovascular, kidney, and overall survival. Because the study period ended in 2019, nsMRA data are entirely absent from t…
1 sources - 4 claims
Triple combination therapy using SGLT2i, GLP-1 RA, and finerenone has been modelled to produce substantial gains in cardiovascular, kidney, and overall survival. Because the study period ended in 2019, nsMRA data are entirely absent from this dataset. The CONFIDENCE trial provided prospective data confirming that combining SGLT2i with finerenone slows disease progression and confers long-term organ-protective benefits. Finerenone is currently recommended in the updated Chinese guideline for patients with T2D and CKD who have albuminuria.